Entity name (all represent body corporate entities unless otherwise specified) Australian or Foreign resident Country of Incorporation and Tax Residency1 Percentage owned (%) Iscotec AB Foreign Sweden 100% CSL Behring AG Foreign Switzerland 100% CSL Behring Biotherapies GmbH Foreign Switzerland 100% CSL Behring Lengnau AG Foreign Switzerland 100% Seqirus AG Foreign Switzerland 100% Vifor (International) AG Foreign Switzerland 100% Vifor Pharma Management AG Foreign Switzerland 100% Vifor Pharma Participations AG Foreign Switzerland 100% Vifor Pharma Switzerland SA Foreign Switzerland 100% CSL Behring Limited Foreign Taiwan 100% CSL Behring Biyoterapi llac Dis Ticaret AS Foreign Turkey 100% CSL Behring UK Limited Foreign UK 100% CSL Finance Plc Foreign UK 100% CSL Behring Holdings Limited Foreign UK 100% Seqirus Holdings UK Limited Foreign UK 100% Seqirus Limited Foreign UK 100% Seqirus UK Limited Foreign UK 100% Seqirus Vaccines Holdings Limited Foreign UK 100% Seqirus Vaccines Limited Foreign UK 100% Vifor Pharma UK Limited Foreign UK 100% CSL Behring LLC Foreign UK 100% CSL Plasma Puerto Rico LLC Foreign USA (Puerto Rico) 100% CSL Plasma Inc. Foreign USA 100% CSL Behring Gene Therapy, Inc. Foreign USA 100% CSLB Holdings Inc. Foreign USA 100% Seqirus USA Inc. Foreign USA 100% Seqirus Inc. Foreign USA 100% Vifor Pharma, Inc. Foreign USA 100% CSL Behring MEA FZ-LLC Foreign UAE 100% Controlled entities (not wholly owned) of CSL Limited4: Cervax Pty. Limited Australian Australia 74% Vifor Fresenius Medical Care Renal Pharma België NV Foreign Belgium 55% Vifor Fresenius Kabi (Beijing) Pharmaceutical Consulting Co. Ltd. Foreign China 55% Vifor Fresenius Medical Care Renal Pharma France S.A.S. Foreign France 55% Fresenius Medical Care Nephrologica Deutschland GmbH Foreign Germany 55% Vifor Fresenius Medical Care Renal Pharma Italia S.r.l. Foreign Italy 55% Vifor Fresenius Medical Care Renal Pharma Nederland B.V. Foreign Netherlands 55% Vifor Fresenius Medical Care Renal Pharma España, S.L. Foreign Spain 55% Vifor Fresenius Medical Care Renal Pharma AG Foreign Switzerland 55% Vifor Fresenius Medical Care Renal Pharma UK Limited Foreign UK 55% Consolidated Entity Disclosure Statement For the Year Ended 30 June 2024 1. All entities have retained the same tax residency as their country of incorporation. 2. Entity is a hybrid trust representing a legal entity that is the trustee of CSL Employee Share Trust which has an Australian tax residency and country of incorporation. 3. Entity represents a limited partnership. 4. Represents a participating entity of a joint venture that is consolidated in the Group’s consolidated financial information. 148 Limited Annual Report 2023/24
RkJQdWJsaXNoZXIy MjE2NDg3